Jacobs Levy Equity Management, Inc Sc Pharmaceuticals Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.9 - $6.11 $319,374 - $500,354	-81,891 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.88 - $6.9 $78,826 - $140,180	-20,316 Reduced 19.88%	81,891 $411,000
Q3 2021 Nov 15, 2021	SELL	$4.93 - $7.15 $179,437 - $260,238	-36,397 Reduced 26.26%	102,207 $680,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $7.38 $12,263 - $17,438	-2,363 Reduced 1.68%	138,604 $847,000
Q1 2021 May 17, 2021	BUY	$5.65 - $7.66 $648,636 - $879,390	114,803 Added 438.78%	140,967 $937,000
Q4 2020 Feb 16, 2021	BUY	$5.17 - $9.41 $135,267 - $246,203	26,164 New	26,164 $138,000
Q1 2020 May 15, 2020	SELL	$5.4 - $10.45 $96,071 - $185,915	-17,791 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.1 - $6.21 $12,943 - $19,604	3,157 Added 21.57%	17,791 $101,000
Q3 2019 Nov 14, 2019	SELL	$3.24 - $7.35 $72,209 - $163,809	-22,287 Reduced 60.36%	14,634 $86,000
Q2 2019 Aug 13, 2019	BUY	$2.48 - $3.76 $32,798 - $49,726	13,225 Added 55.81%	36,921 $118,000
Q1 2019 May 14, 2019	BUY	$2.84 - $4.18 $67,296 - $99,049	23,696 New	23,696 $71,000

37.1M

110K

12.1K

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $92.9M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.